Trabalhos ReceptaBio
Single-agent Activity of a Novel PD-1 Inhibitor, AGEN2034, in Recurrent Ovarian Cancer. O’Malley, et al.
NaPi2b Expression in a Large Surgical Non-Small Cell Lung Cancer (NSCLC) Cohort. Mitchell P, et al.
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer. Drescher, et al.
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors. Coward, et al.
Veja o poster
Phase One Open-Label, Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation. Moore, et al.
Veja o poster
Desenvolvendo medicamentos oncológicos inovadores para a população brasileira.
BR
EN